Paul Saladino· MD
when you compare that to an AG matap control from Miami Heart it's there's no statistically significant difference
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
when you compare that to an AG matap control from Miami Heart it's there's no statistically significant difference
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
if apob causes atherosclerosis then why does your group with a very elevated LDL for an average of 4.7 years not have a statistically significant I would say marketly different greater plaque burden than an AG match control from Miami Heart with lower amounts of LDL
there's not enough power in the study with only 80 to 80 comparison to make that a statistically significant difference but you have a trend toward lower which is incredible
there's no correlation there's no correlation in our group or in the Miami Heart group there's just no correlation between uh detected LDL levels at Baseline and resulting plaque
but you have a trend toward lower which is incredible